Otonomy, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. In addition, it develops OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties; OTO-5XX, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone619-323-2200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.24 million
Profitability
Miscellaneous
Employees53
OptionableOptionable
Otonomy (NASDAQ:OTIC) Frequently Asked Questions
What is Otonomy's stock symbol?
Otonomy trades on the NASDAQ under the ticker symbol "OTIC."
How were Otonomy's earnings last quarter?
Otonomy Inc (NASDAQ:OTIC) released its quarterly earnings data on Tuesday, November, 6th. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.06. The biopharmaceutical company had revenue of $0.11 million for the quarter, compared to analysts' expectations of $0.25 million. Otonomy had a negative return on equity of 54.24% and a negative net margin of 6,983.40%. View Otonomy's Earnings History.
When is Otonomy's next earnings date?
What price target have analysts set for OTIC?
4 analysts have issued 1 year target prices for Otonomy's stock. Their predictions range from $9.00 to $10.00. On average, they expect Otonomy's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 377.4% from the stock's current price. View Analyst Price Targets for Otonomy.
What is the consensus analysts' recommendation for Otonomy?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Otonomy.
Has Otonomy been receiving favorable news coverage?
News stories about OTIC stock have trended very positive this week, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Otonomy earned a coverage optimism score of 3.7 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of Otonomy's key competitors?
Some companies that are related to Otonomy include Tyme Technologies (TYME), Intec Pharma (NTEC), Adamas Pharmaceuticals (ADMS), Axsome Therapeutics (AXSM), AVEO Pharmaceuticals (AVEO), Acer Therapeutics (ACER), resTORbio (TORC), Aldeyra Therapeutics (ALDX), Seres Therapeutics (MCRB), Dova Pharmaceuticals (DOVA), Magenta Therapeutics (MGTA), TAIWAN LIPOSOME/S (TLC), Syros Pharmaceuticals (SYRS), Strongbridge Biopharma (SBBP) and MannKind (MNKD).
Who are Otonomy's key executives?
Otonomy's management team includes the folowing people:
- Dr. Jay B. Lichter, Co-Founder & Chairman (Age 57)
- Dr. David Allen Weber, Pres, CEO & Director (Age 59)
- Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 57)
- Dr. Kathie M. Bishop, Chief Scientific Officer (Age 53)
- Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel
How do I buy shares of Otonomy?
Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Otonomy's stock price today?
One share of OTIC stock can currently be purchased for approximately $1.99.
How big of a company is Otonomy?
Otonomy has a market capitalization of $60.95 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe.
What is Otonomy's official website?
How can I contact Otonomy?
Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]
MarketBeat Community Rating for Otonomy (NASDAQ OTIC)
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
